A Phase 3 interventional study of efgartigimod PH20 SC and efgartigimod IV in Generalized Myasthenia Gravis, sponsored by argenx. Completed at 47 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.
Sponsored by argenx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 10 in phase 3, and was the 4th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:
argenx · Sites in United States, Belgium, Germany and 5 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 65+
argenx · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18+
Clinique Neuro-Outaouais · Sites in Canada
Ages 18–80
By country, each count listing its studies:
efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 4
First in 2016; this study’s year is marked. 4 started in 2021.
This study's enrollment of 110 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 55 across the 20 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 8 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
18 studies in Myasthenia Gravis by argenx: 9 open now, 12 under way, 5 of them phase 3. Of 6 finished, 6 (100%) have results posted.
Among the 18 studies in Myasthenia Gravis by argenx, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 4th registered.
argenx’s Myasthenia Gravis studies by the year they started, since 2016.
7 of the studies testing efgartigimod alfa in Myasthenia Gravis that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06765161Phase 3Clinique Neuro-OutaouaisEfgartigimod in IVIG Dependent Myasthenia Gravis Patients | 2027-01-06 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT07231523Phase 3Shanghai Zhongshan HospitalEFG vs IVIG in TAMG | 2027-06-01 |
| NCT06392386Phase 3argenxA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | 2027-09 |
| NCT06221501Shanghai Zhongshan HospitalPerioperative Efgartigimod for Thymoma and Myasthenia Gravis | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among argenx’s 18 in Myasthenia Gravis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) as compared to efgartigimod IV infused in patients with generalized myasthenia gravis (gMG). The study duration is approximately 12 weeks. After screening, patients will be randomized to receive either efgartigimod infusions or efgartigimod PH20 subcutaneously (SC)
Main objective of the trial: To demonstrate that the pharmacodynamic (PD) effect of injections of 1000 mg efgartigimod PH20 SC (efgartigimod co-formulated with recombinant humanhyaluronidase PH20 for subcutaneous administration), administered once weekly for 4 administrations, is NI (noninferior) to IV infusions of efgartigimod (efgartigimod formulation for intravenous infusion) at a dose of 10 mg/kg administered once weekly for 4 administrations.
Secondary objectives: To compare the PD effect of efgartigimod PH20 SC and efgartigimod IV over time; To evaluate the pharmacokinetics (PK) of efgartigimod PH20 SC and efgartigimod IV; To evaluate the safety, tolerability, and immunogenicity of efgartigimod PH20 SC and efgartigimod IV; To evaluate the clinical efficacy of efgartigimod PH20 SC and efgartigimod IV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Bullet list of each inclusion criterium:
Diagnosed with generalized Myasthenia Gravis (gMG) with confirmed documentation and supported by at least 1 of the following:
Exclusion Criteria:
Bullet list of each exclusion criterium:
Has any of the following medical conditions:
History of unless deemed cured by adequate treatment with no evidence of reoccurrence for ≥3 years before the first administration of the IMP. Participants with the following cancers can be included at any time:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
Biological: efgartigimod PH20 SC
Patients receiving efgartigimod intravenous (IV) treatment
Biological: efgartigimod IV
Drug pages: Efgartigimod alfa · Hyaluronidase (human recombinant)
Subcutaneous injection with efgartigimod PH20 SC
Intravenous infusion of efgartigimod
Percent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set)
ANCOVA Analysis of Percent Change From Baseline in Total IgG Level at Day 29 (ie, 7 days after the fourth IV or SC administration).
Time frame: From week 0 to week 4
Percent Change From Baseline in Total IgG Levels Over Time (mITT Analysis Set)
Total IgG level percent change from baseline over time for the overall population.
Time frame: From baseline to week 10
Percent Change From Baseline in AChR-Ab Levels Over Time in AChR- Ab Positive Patients (mITT Analysis Set)
Percent reduction from baseline in AChR-Ab levels over time in AChR-Ab positive patients measured in mITT Analysis Set. Descriptive statistics have been used for this secondary end point.
Time frame: From baseline to week 10
Percent Change From Baseline in IgG Subtype Levels Over Time (mITT Analysis Set)
Median (IQR) Percent Change From Baseline for the IgG Subtypes (IgG1, IgG2, IgG3, and IgG4) in the Overall Population. The highest number of patients among all weeks for the analysis is chosen for each arm. Descriptive statistics have been used for this secondary end point.
Time frame: Baseline to week 10
AUEC of the Percent Change From Baseline in Total IgG Level (mITT Analysis Set)
AUEC of the percent reduction from baseline total IgG per dosing interval (days 1-8, days 8-15, days 15-22, and days 22-29), days 1-29, days 1-57 and over the entire study (days 1-71). The highest number of patients among all weeks for the analysis is chosen for each arm. Descriptive statistics have been used for this secondary end point.
Time frame: From baseline to week 10
Еfgartigimod IV and PH20 SC Serum Pharmacokinetic Parameter Ctrough
Evaluation of observed predose concentration (Ctrough) (after all doses for the IV and SC treatment arms). The analysis will present data from Week 1 to Week 4. Descriptive statistics have been used for this secondary end point.
Time frame: From Week 1 to Week 4.
Efgartigimod IV Serum Pharmacokinetic Parameter Cmax
Evaluation of maximum observed concentration (Cmax) (after all doses for the IV treatment arm). The analysis will present data from Baseline to Week 3. Descriptive statistics have been used for this secondary end point.
Time frame: From Baseline to Week 3
Incidence of ADA Against Efgartigimod (Safety Analysis Set)
Incidence of antidrug antibodies (ADA) against Efgartigimod in the overall population. ADA analysis is performed with a validated ELISA in a 3-tiered approach (ADA screening analysis, confirmatory analysis and a titration assay). Descriptive statistics have been used for this secondary end point.
Time frame: From baseline to week 10
Incidence of Antibodies Against rHuPH20 in the SC Treatment Arm (Safety Analysis Set)
Incidence of antibodies against rHuPH20 in the Efgartigimod PH20 SC Arm. antibody analysis is performed with a validated ELISA in a 3-tiered approach (screening analysis, confirmatory analysis and a titration assay) Descriptive statistics have been used for this secondary end point.
Time frame: From baseline to week 10
Incidence and Severity of AEs and SAEs (Safety Analysis Set)
Evaluation of incidence and severity of treatment-emergent adverse events (TEAEs) and incidence of serious AEs (SAEs). Descriptive statistics have been used for this secondary end point.
Time frame: From baseline to week 10
MG-ADL Responders (ITT Analysis Set)
Evaluation of number and percentage of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders in the overall population. The MG-ADL is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life, including talking, chewing, swallowing, breathing, brushing their teeth, combing their hair, or getting up from a chair. The MG-ADL also assesses double vision and eyelid droop. It is a discrete quantitative variable in which the 8 items are rated by the participant on a scale of 0 to 3. The total score can range from 0 to 24, with higher total scores indicating more impairment. A participant was considered a MG-ADL responder if he/she showed a reduction of at least 2 points from baseline on the MG-ADL score for at least 4 consecutive weeks. Descriptive statistics have been used for this secondary end point.
Time frame: From baseline to week 10
QMG Responders (ITT Analysis Set)
Evaluation of number and percentage of Quantitative Myasthenia Gravis (QMG) responders in the overall population (ITT Analysis Set). Descriptive statistics have been used for this secondary end point. One subject in the EFG IV arm had no post-baseline QMG assessment and thus was excluded from the denominator.
Time frame: From Baseline to Week 10
Change From Baseline in MG-ADL Total Score Over Time (ITT Analysis Set)
Evaluation of MG-ADL Total Score Change from baseline over time for the overall population (ITT Analysis Set). Descriptive statistics have been used for this secondary end point. The MG-ADL is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life, including talking, chewing, swallowing, breathing, brushing their teeth, combing their hair, or getting up from a chair. The MG-ADL also assesses double vision and eyelid droop. It is a discrete quantitative variable in which the 8 items are rated by the participant on a scale of 0 to 3. The total score can range from 0 to 24, with higher total scores indicating more impairment. A participant was considered a MG-ADL responder if he/she showed a reduction of at least 2 points from baseline on the MG-ADL score for at least 4 consecutive weeks.
Time frame: From baseline to week 10
Change From Baseline in QMG Score Over Time (ITT Analysis Set)
Evaluation of QMG Total Score change from baseline over time for the overall population (ITT Analysis Set). The QMG (Quantitative Myasthenia Gravis) quantifies disease severity based on impairments of body function and structures as defined by the International Classification of Functioning, Disability and Health. The QMG consists of 13 items that assess ocular, bulbar, and limb function. Six of the 13 items are timed endurance tests measured in seconds. Each item has a possible score from 0 to 3. The total possible score is 39, where higher total scores indicate more severe impairments. It is based on qualitative testing of specific muscle groups to assess limb function. Descriptive statistics have been used for this secondary end point. A participant was considered a QMG responder if he/she showed a reduction of at least 3 points from baseline on the QMG score for at least 4 consecutive weeks.
Time frame: From baseline to week 10
Participant's evaluation of eligibility was performed at screening and confirmed at randomization visit 1. The overall study duration per subject was approximately 12 weeks spanning the study periods - 2 weeks for screening, 3 weeks for treatment, and 7 weeks for follow-up.
| Milestone | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Started | 55 | 55 |
| Completed | 52 | 55 |
| Not completed | 3 | 0 |
| Withdrew: Other - due to personal reason | 1 | 0 |
| Withdrew: Adverse event | 2 | 0 |
ANCOVA Analysis of Percent Change From Baseline in Total IgG Level at Day 29 (ie, 7 days after the fourth IV or SC administration).
| percent | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Percent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set) | -66.4 (-68.91 to -63.86) | -62.2 (-64.67 to -59.72) |
Total IgG level percent change from baseline over time for the overall population.
| percent | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Week 1 | -40.1 ± 1.45 | -39.6 ± 1.51 |
| Week 2 | -56.9 ± 1.57 | -55.1 ± 1.85 |
| Week 3 | -62.2 ± 1.41 | -59 ± 2 |
| Week 4 | -64.7 ± 1.95 | -62.3 ± 1.24 |
| Week 5 | -57.4 ± 1.7 | -49.9 ± 2.17 |
| Week 6 | -44 ± 2.52 | -38.9 ± 2.24 |
| Week 7 | -31.2 ± 4.67 | -25.3 ± 2.78 |
| Week 8 | -8.9 ± 8.65 | -14.6 ± 3.13 |
| Week 10 | 7.8 ± 7.78 | -3.1 ± 3.82 |
Percent reduction from baseline in AChR-Ab levels over time in AChR-Ab positive patients measured in mITT Analysis Set. Descriptive statistics have been used for this secondary end point.
| percent | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Week 1 | -42.5 ± 1.5 | -43.7 ± 1.55 |
| Week 2 | -57.4 ± 1.39 | -55.1 ± 1.52 |
| Week 3 | -61.8 ± 1.6 | -59.2 ± 1.66 |
| Week 4 | -62.2 ± 1.76 | -59.6 ± 1.74 |
| Week 5 | -55.3 ± 1.52 | -47.2 ± 2.98 |
| Week 6 | -40.4 ± 3.13 | -29.9 ± 4.61 |
| Week 7 | -26.7 ± 4.76 | -15.8 ± 5.63 |
| Week 8 | -14.5 ± 7.82 | -7.1 ± 6.02 |
| Week 10 | 13.5 ± 23.16 | 10.3 ± 7.85 |
Median (IQR) Percent Change From Baseline for the IgG Subtypes (IgG1, IgG2, IgG3, and IgG4) in the Overall Population. The highest number of patients among all weeks for the analysis is chosen for each arm. Descriptive statistics have been used for this secondary end point.
| Percent change | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Percent change from baseline at week 4 IgG1 | -71 (-79.3 to -56.6) | -68.4 (-73 to -61.5) |
| Percent change from baseline at week 4 IgG2 | -65.6 (-72.2 to -58.1) | -64.5 (-73 to -57.4) |
| Percent change from baseline at week 4 IgG3 | -69.6 (-78.3 to -58.4) | -64.7 (-76.9 to -59.5) |
| Percent change from baseline at week 4 IgG4 | -56.4 (-64.4 to -37.2) | -55.5 (-64.2 to -42.1) |
AUEC of the percent reduction from baseline total IgG per dosing interval (days 1-8, days 8-15, days 15-22, and days 22-29), days 1-29, days 1-57 and over the entire study (days 1-71). The highest number of patients among all weeks for the analysis is chosen for each arm. Descriptive statistics have been used for this secondary end point.
| percent days | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Days 1-8 (baseline-week 1) | -138.9 ± 5.48 | -139.1 ± 5.67 |
| Days 8-15 (week 1-week 2) | -341.9 ± 9.9 | -328.3 ± 10.98 |
| Days 15-22 (week 2-week 3) | -416.0 ± 12.06 | -399.8 ± 14.46 |
| Days 22-29 (week 3-week 4) | -447.3 ± 9.24 | -427.0 ± 9.76 |
| Days 1-29 (baseline-week 4) | -1332.5 ± 30.78 | -1311.6 ± 26.35 |
| Days 1-57 (baseline-week 8) | -2515.9 ± 96.98 | -2387.6 ± 77.61 |
| Days 1-71 (baseline-week 10) | -2562.9 ± 171.86 | -2500.3 ± 116.10 |
Evaluation of observed predose concentration (Ctrough) (after all doses for the IV and SC treatment arms). The analysis will present data from Week 1 to Week 4. Descriptive statistics have been used for this secondary end point.
| μg/mL | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Ctrough week 1 | 18.3 ± 8.05 | 16.4 ± 33.0 |
| Ctrough week 2 | 21.4 ± 8.36 | 14.0 ± 6.92 |
| Ctrough week 3 | 22.5 ± 9.61 | 15.2 ± 8.05 |
| Ctrough week 4 | 22.0 ± 8.12 | 14.9 ± 6.43 |
Evaluation of maximum observed concentration (Cmax) (after all doses for the IV treatment arm). The analysis will present data from Baseline to Week 3. Descriptive statistics have been used for this secondary end point.
| μg/mL | Efgartigimod IV |
|---|---|
| Cmax Baseline | 199 ± 62.8 |
| Cmax week 1 | 215 ± 63.0 |
| Cmax week 2 | 211 ± 75.0 |
| Cmax week 3 | 206 ± 59.5 |
Incidence of antidrug antibodies (ADA) against Efgartigimod in the overall population. ADA analysis is performed with a validated ELISA in a 3-tiered approach (ADA screening analysis, confirmatory analysis and a titration assay). Descriptive statistics have been used for this secondary end point.
| Percent of patients | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Incidence of ADA Against Efgartigimod (Safety Analysis Set) | 34.5 | 20.0 |
Incidence of antibodies against rHuPH20 in the Efgartigimod PH20 SC Arm. antibody analysis is performed with a validated ELISA in a 3-tiered approach (screening analysis, confirmatory analysis and a titration assay) Descriptive statistics have been used for this secondary end point.
| Percent of patients | Efgartigimod PH20 SC |
|---|---|
| Incidence of Antibodies Against rHuPH20 in the SC Treatment Arm (Safety Analysis Set) | 5.5 |
Evaluation of incidence and severity of treatment-emergent adverse events (TEAEs) and incidence of serious AEs (SAEs). Descriptive statistics have been used for this secondary end point.
| Percent of patients | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| ≥1 AE | 67.3 | 50.9 |
| ≥1 SAE | 14.5 | 7.3 |
| ≥1 Grade 3 or higher AE | 16.4 | 7.3 |
| ≥1 AESI | 18.2 | 16.4 |
| ≥1 Injection site reaction (localized) | 38.2 | 1.8 |
| ≥1 Infusion- or injection-related reaction | 25.5 | 3.6 |
| ≥1 Fatal AE | 0 | 0 |
| ≥1 Treatment-related AE according to PI | 43.6 | 21.8 |
| ≥1 Procedure-related AE according to PI | 25.5 | 3.6 |
| ≥1 Treatment-related SAE | 0 | 0 |
| ≥1 AE for which the IMP was interrupted | 1.8 | 0 |
| ≥1 AE for which the IMP was discontinued | 3.6 | 0 |
Evaluation of number and percentage of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders in the overall population. The MG-ADL is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life, including talking, chewing, swallowing, breathing, brushing their teeth, combing their hair, or getting up from a chair. The MG-ADL also assesses double vision and eyelid droop. It is a discrete quantitative variable in which the 8 items are rated by the participant on a scale of 0 to 3. The total score can range from 0 to 24, with higher total scores indicating more impairment. A participant was considered a MG-ADL responder if he/she showed a reduction of at least 2 points from baseline on the MG-ADL score for at least 4 consecutive weeks. Descriptive statistics have been used for this secondary end point.
| percent | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| MG-ADL Responders (ITT Analysis Set) | 69.1 | 69.1 |
Evaluation of number and percentage of Quantitative Myasthenia Gravis (QMG) responders in the overall population (ITT Analysis Set). Descriptive statistics have been used for this secondary end point. One subject in the EFG IV arm had no post-baseline QMG assessment and thus was excluded from the denominator.
| percent | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| QMG Responders (ITT Analysis Set) | 65.5 | 51.9 |
Evaluation of MG-ADL Total Score Change from baseline over time for the overall population (ITT Analysis Set). Descriptive statistics have been used for this secondary end point. The MG-ADL is an 8-item patient-reported scale that assesses MG symptoms and their effects on daily activities. It evaluates a participant's capacity to perform different activities in their daily life, including talking, chewing, swallowing, breathing, brushing their teeth, combing their hair, or getting up from a chair. The MG-ADL also assesses double vision and eyelid droop. It is a discrete quantitative variable in which the 8 items are rated by the participant on a scale of 0 to 3. The total score can range from 0 to 24, with higher total scores indicating more impairment. A participant was considered a MG-ADL responder if he/she showed a reduction of at least 2 points from baseline on the MG-ADL score for at least 4 consecutive weeks.
| Total score on a scale | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Week 1 | -2.2 ± 0.33 | -2.0 ± 0.30 |
| Week 2 | -3.6 ± 0.40 | -3.2 ± 0.35 |
| Week 3 | -4.7 ± 0.36 | -4.3 ± 0.33 |
| Week 4 | -5.1 ± 0.38 | -4.7 ± 0.37 |
| Week 5 | -4.9 ± 0.36 | -4.3 ± 0.41 |
| Week 6 | -4.2 ± 0.35 | -3.7 ± 0.44 |
| Week 7 | -3.9 ± 0.35 | -3.6 ± 0.44 |
| Week 8 | -3.3 ± 0.34 | -2.9 ± 0.4 |
| Week 10 | -2.2 ± 0.44 | -2.1 ± 0.43 |
Evaluation of QMG Total Score change from baseline over time for the overall population (ITT Analysis Set). The QMG (Quantitative Myasthenia Gravis) quantifies disease severity based on impairments of body function and structures as defined by the International Classification of Functioning, Disability and Health. The QMG consists of 13 items that assess ocular, bulbar, and limb function. Six of the 13 items are timed endurance tests measured in seconds. Each item has a possible score from 0 to 3. The total possible score is 39, where higher total scores indicate more severe impairments. It is based on qualitative testing of specific muscle groups to assess limb function. Descriptive statistics have been used for this secondary end point. A participant was considered a QMG responder if he/she showed a reduction of at least 3 points from baseline on the QMG score for at least 4 consecutive weeks.
| Total score | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Week 1 | -3 ± 0.48 | -2 ± 0.44 |
| Week 2 | -4.3 ± 0.58 | -3.4 ± 0.44 |
| Week 3 | -5.7 ± 0.61 | -4.5 ± 0.5 |
| Week 4 | -6.1 ± 0.62 | -5.2 ± 0.52 |
| Week 5 | -5.9 ± 0.61 | -5 ± 0.57 |
| Week 6 | -5.2 ± 0.6 | -5 ± 0.61 |
| Week 7 | -3.9 ± 0.61 | -4.1 ± 0.55 |
| Week 8 | -3.7 ± 0.66 | -3.3 ± 0.53 |
| Week 10 | -2.3 ± 0.6 | -2.8 ± 0.53 |
Collected over up to 12 weeks (throughout the treatment period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod PH20 SC | 0/55 (0%) | 8/55 (14.5%) | 37/55 (67.3%) |
| Efgartigimod IV | 0/55 (0%) | 4/55 (7.3%) | 23/55 (41.8%) |
| Event | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Myasthenia gravisNervous system disorders | 5/55 | 1/55 |
| Humerus fractureInjury, poisoning and procedural complications | 1/55 | 0/55 |
| Cardiac failure congestiveCardiac disorders | 0/55 | 1/55 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/55 | 1/55 |
| Optic neuritisNervous system disorders | 1/55 | 0/55 |
| SyncopeNervous system disorders | 1/55 | 0/55 |
| Chest painGeneral disorders | 0/55 | 1/55 |
| Testicular cystReproductive system and breast disorders | 0/55 | 1/55 |
| CellulitisInfections and infestations | 1/55 | 0/55 |
| Event | Efgartigimod PH20 SC | Efgartigimod IV |
|---|---|---|
| Injection site rashGeneral disorders | 8/55 | 0/55 |
| HeadacheNervous system disorders | 7/55 | 7/55 |
| Injection site erythemaGeneral disorders | 7/55 | 0/55 |
| Myasthenia gravisNervous system disorders | 6/55 | 1/55 |
| Injection site pruritusGeneral disorders | 5/55 | 0/55 |
| Injection site bruisingGeneral disorders | 4/55 | 0/55 |
| ContusionInjury, poisoning and procedural complications | 0/55 | 3/55 |
| FallInjury, poisoning and procedural complications | 1/55 | 3/55 |
| FatigueGeneral disorders | 2/55 | 3/55 |
| Injection site painGeneral disorders | 3/55 | 0/55 |
ITT analysis set: All randomized participants who were exposed to the IMP. mITT analysis set: All randomized participants with a value for total IgG levels at baseline and at least 1 postbaseline time point. Safety analysis set: All randomized participants who were exposed to IMP. PK analysis set: A subset of the safety analysis set with at least 1 post dose PK measurement.
| Age, Categorical(Participants) | Efgartigimod PH20 SC | Efgartigimod IV | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 43 | 37 | 80 |
| >=65 years | 12 | 18 | 30 |
| Age, Continuous(years) | Efgartigimod PH20 SC | Efgartigimod IV | Total |
|---|---|---|---|
| Median | 53.0 (19 to 84) | 59.0 (24 to 83) | 53.5 (19 to 84) |
| Sex: Female, Male(Participants) | Efgartigimod PH20 SC | Efgartigimod IV | Total |
|---|---|---|---|
| Female | 31 | 34 | 65 |
| Male | 24 | 21 | 45 |
| Race (NIH/OMB)(Participants) | Efgartigimod PH20 SC | Efgartigimod IV | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 50 | 51 | 101 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Nov 2021, 8 months.
Results were first posted in Feb 2023, 1 year 3 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 8 months is below that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)